**4.1 The population**

This phase I/II study was conducted in seven French centres. Patients (> 18 years and who were able to give informed consent) with newly diagnosed, supratentorial, unresectable but histologically confirmed glioblastoma (astrocytoma grade IV according to the WHO classification), with a WHO performance status of 0-2 were eligible (Beauchesne et al., 2010). Patients were included based on local pathology. Patients with an estimated survival of less than 3 months, who had undergone partial or complete tumor resection, or who had previously received prior radiation therapy were not eligible. The primary end-points of the study were the treatment-related toxicity and tolerability (Beauchesne et al., 2010). Secondary end-points were progression-free survival (PFS) and overall survival (OS) of glioblastoma patients (Beauchesne et al., 2010).
